Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy.
Where this comes from
- Record sourced from PubMed, PMID 33931226.
- Also identified by DOI 10.1016/j.kint.2021.04.007 and PMC identifier 8055920.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Kidney International, the initial experience regarding the immunogenicity of prior coronavirus disease 2019 (COVID-19) infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is durability of immune response after COVID-19 infection. Although immune response to the first dose of vaccine is less in infection-naïve patients than healthy individuals in both groups, after the second vaccine dose a significant portion of patients receiving maintenance dialysis develop robust antibody titers, whereas kidney transplant recipients show a less-strong immune response.
Medical subject headings
- COVID-19
- COVID-19 Vaccines
- Kidney Transplantation
- Renal Dialysis